Epigallocatechin Gallate Remodelling of Hfq Amyloid-Like Region Affects Escherichia coli Survival
Laboratoire Léon Brillouin LLB, CEA, CNRS UMR12, Université Paris Saclay, CEA Saclay, 91191 Gif-sur-Yvette, France
Synchrotron SOLEIL, L’Orme des Merisiers, Saint Aubin BP48, 91192, Gif-sur-Yvette, France
Institut Curie, INSERM U1196, and CNRS UMR9187, 91405 Orsay Cedex, France
UFR SDV, Université Paris Diderot, Sorbonne Paris Cité, 75013 Paris, France
Authors to whom correspondence should be addressed.
Pathogens 2018, 7(4), 95; https://doi.org/10.3390/pathogens7040095
Received: 11 November 2018 / Revised: 22 November 2018 / Accepted: 26 November 2018 / Published: 1 December 2018
(This article belongs to the Special Issue Inactivate Bacterial Resistance Mechanisms)
Hfq is a pleiotropic regulator that has key roles in the control of genetic expression. The protein noticeably regulates translation efficiency and RNA decay in Gram-negative bacteria, due to the Hfq-mediated interaction between small regulatory noncoding RNA and mRNA. This property is of primary importance for bacterial adaptation and virulence. We have previously shown that the Hfq E. coli protein, and more precisely its C-terminal region (CTR), self-assembles into an amyloid-like structure. In the present work, we demonstrate that epigallocatechin gallate (EGCG), a major green tea polyphenol compound, targets the Hfq amyloid region and can be used as a potential antibacterial agent. We analysed the effect of this compound on Hfq amyloid fibril stability and show that EGCG both disrupts Hfq-CTR fibrils and inhibits their formation. We show that, even if EGCG affects other bacterial amyloids, it also specifically targets Hfq-CTR in vivo. Our results provide an alternative approach for the utilisation of EGCG that may be used synergistically with conventional antibiotics to block bacterial adaptation and treat infections.